Ken Griffin Mirati Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $44.7 Million - $66.4 Million	-1,064,827 Reduced 94.11%	66,611 $3.91 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $18.1 Million - $29.5 Million	649,620 Added 134.83%	1,131,438 $49.3 Million
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $14.1 Million - $19.4 Million	391,174 Added 431.55%	481,818 $17.4 Million
Q1 2023 May 15, 2023	SELL	$36.54 - $54.26 $1.09 Million - $1.62 Million	-29,859 Reduced 24.78%	90,644 $3.37 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $1.3 Million - $3.12 Million	31,617 Added 35.57%	120,503 $5.46 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $723,877 - $1.05 Million	12,166 Added 15.86%	88,886 $6.21 Million
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $2.27 Million - $5.14 Million	57,909 Added 307.85%	76,720 $5.15 Million
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $2.15 Million - $4.28 Million	-28,338 Reduced 60.1%	18,811 $1.55 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $1.22 Million - $1.76 Million	9,259 Added 24.44%	47,149 $6.92 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $55.5 Million - $74.5 Million	-419,707 Reduced 91.72%	37,890 $6.7 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $6.68 Million - $8.34 Million	46,382 Added 11.28%	457,597 $73.9 Million
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $37.8 Million - $52.7 Million	237,842 Added 137.19%	411,215 $70.4 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $26.1 Million - $38.6 Million	160,778 Added 1276.52%	173,373 $38.1 Million
Q3 2020 Nov 16, 2020	SELL	$113.26 - $167.27 $5.07 Million - $7.49 Million	-44,787 Reduced 78.05%	12,595 $2.09 Million
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $1.99 Million - $3.32 Million	-27,615 Reduced 32.49%	57,382 $6.55 Million
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $3.14 Million - $5.23 Million	-44,996 Reduced 34.61%	84,997 $6.53 Million
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $6.56 Million - $11.9 Million	92,686 Added 248.44%	129,993 $16.8 Million
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $13.1 Million - $18.4 Million	-167,933 Reduced 81.82%	37,307 $2.91 Million
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $10.9 Million - $19.1 Million	182,391 Added 798.24%	205,240 $21.1 Million
Q1 2019 May 15, 2019	BUY	$43.65 - $78.95 $105,851 - $191,453	2,425 Added 11.87%	22,849 $0
Q4 2018 Feb 14, 2019	SELL	$32.0 - $47.43 $658,464 - $975,967	-20,577 Reduced 50.19%	20,424 $866,000
Q3 2018 Nov 13, 2018	BUY	$47.1 - $62.7 $1.3 Million - $1.73 Million	27,512 Added 203.96%	41,001 $0
Q2 2018 Aug 10, 2018	SELL	$26.05 - $52.4 $929,646 - $1.87 Million	-35,687 Reduced 72.57%	13,489 $0
Q1 2018 May 11, 2018	BUY	$17.2 - $34.95 $329,001 - $668,523	19,128 Added 63.66%	49,176 $1.51 Million
Q4 2017 Feb 09, 2018	BUY	$12.65 - $19.0 $90,991 - $136,667	7,193 Added 31.47%	30,048 $548,000
Q3 2017 Nov 09, 2017	BUY	$4.7 - $11.7 $107,418 - $267,403	22,855	22,855 $268,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account